Showing results (111-120 of 120) with videos related to
Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Biomedicines|April 29, 2025
lncRNA EGOT Is the Marker of HPV Infection and a Prognostic Factor for HNSCC PatientsTomasz Kolenda, Piotr Białas, Kacper Guglas, et al.The Lancet. Oncology|October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.The New England Journal of Medicine|November 18, 2014
Improved overall survival in melanoma with combined dabrafenib and trametinibCaroline Robert, Boguslawa Karaszewska, Jacob Schachter, et al.European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.The New England Journal of Medicine|June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic MelanomaCaroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.Cell Research|January 14, 2015
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25Dalil Hannani, Marie Vétizou, David Enot, et al.International Journal of Cancer|August 15, 2003
Hereditary ovarian cancer in PolandJanusz Menkiszak, Jacek Gronwald, Bohdan Górski, et al.International Journal of Cancer|May 18, 2004
A high proportion of founder BRCA1 mutations in Polish breast cancer familiesBohdan Górski, Anna Jakubowska, Tomasz Huzarski, et al.Pageof 12